TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma

Cancer Letters

Volumn 369, Issue 2, 2015, Pages 298-306

  Zhou, Zhixia ^a   Yu, Xin ^a   Zhang, Jian ^a   Tian, Zhigang ^b   Zhang, Cai ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cross talk; DC; Hepatocellular carcinoma (HCC); NK cell; TLR7 8 agonist

Indexed keywords

GAMMA INTERFERON; GARDIQUIMOD; INTERLEUKIN 12; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL CONTACT; CELL INTERACTION; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER CELL CARCINOMA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; LIVER TUMOR; METABOLISM; NUDE MOUSE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84945293359     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.09.017     Document Type: Article

References (41)

1. Kirkwood J.M., Butterfield L.H., Tarhini A.A., Zarour H., Kalinski P., Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin 2012, 62:309-335.
2. Breous E., Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J. Hepatol 2011, 54:830-834.
3. Carballido E., Veliz M., Komrokji R., Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control 2012, 19:54-67.
4. Kobayashi N., Hong C., Klinman D.M., Shirota H. Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. J. Immunol 2013, 190:1882-1889.
5. Westwood J.A., Haynes N.M., Sharkey J., McLaughlin N., Pegram H.J., Schwendener R.A., et al. Toll-like receptor triggering and T-cell costimulation induce potent antitumor immunity in mice. Clin. Cancer Res 2009, 15:7624-7633.
6. Smits E.L., Ponsaerts P., Berneman Z.N., Van Tendeloo V.F. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008, 13:859-875.
7. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X.H., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol 2005, 174:1259-1268.
8. Cooper M.A., Fehniger T.A., Fuchs A., Colonna M., Caligiuri M.A. NK cell and DC interactions. Trends Immunol 2004, 25:47-52.
9. Jacobs B., Ullrich E. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions?. Curr. Med. Chem 2012, 19:1771-1779.
10. Han Q.J., Zhang C., Zhang J., Tian Z.G. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene i-dependent manner. Hepatology 2011, 54:1179-1189.
11. Zhang C., Wang Y.P., Zhou Z.X., Zhang J., Tian Z.G. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol. Immun 2009, 58:1275-1285.
12. Drobits B., Holcmann M., Amberg N., Swiecki M., Grundtner R., Hammer M., et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest 2012, 122:575-585.
13. Ma F., Zhang J.H., Zhang J., Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell. Mol. Immunol 2010, 7:381-388.
14. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
15. Hart O.M., Athie-Morales V., O'Connor G.M., Gardiner C.M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J. Immunol 2005, 175:1636-1642.
16. Zhu J.A., Huang X.P., Yang Y.P. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther 2008, 16:1300-1307.
17. Ferlazzo G., Pack M., Thomas D., Paludan C., Schmid D., Strowig T., et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs,. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16606-16611.
18. Prestwich R.J., Errington F., Steele L.P., Ilett E.J., Morgan R.S.M., et al. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J. Immunol 2009, 183:4312-4321.
19. Van Elssen C.H.M.J., Vanderlocht J., Oth T., Senden-Gijsbers B.L.M.G., Germeraad W.T.V., Bos G.M.J. Inflammation restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood 2011, 118:2473-2482.
20. Simhadri V.L., Hansen H.P., Simhadri V.R., Reiners K.S., Bessler M., Engert A., et al. A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells. Biol. Chem 2012, 393:101-106.
21. Broomfield S.A., van der Most R.G., Prosser A.C., Mahendran S., Tovey M.G., Smyth M.J., et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol 2009, 182:5217-5224.
22. Lee M., Park C.S., Lee Y.R., Im S.A., Song S., Lee C.K. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch. Pharm. Res 2014, 37:1234-1240.
23. Tato C.M., Villarino A., Caamaño J.H., Boothby M., Hunter C.A. Inhibition of NF-kappa B activity in T and NK cells results in defective effector cell expansion and production of IFN-gamma required for resistance to Toxoplasma gondii. J. Immunol 2003, 170:3139-3146.
24. Zhou J., Zhang J., Lichtenheld M.G., Meadows G.G. A role for NF-κB activation in perforin expression of NK cells upon IL-2 receptor signaling. J. Immunol 2002, 169:1319-1325.
25. He S., Chu J., Wu L.C., Mao H., Peng Y., Alvarez-Breckenridge C.A., et al. MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood 2013, 121:4663-4671.
26. Clifford H.D., Yerkovich S.T., Khoo S.K., Zhang G.C., Upham J., Le Souef P.N., et al. Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine. Immunogenetics 2012, 64:219-228.
27. Scholch S., Rauber C., Tietz A., Rahbari N.N., Bork U., Schmidt T., et al. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 2015, 6:4663-4676.
28. Singh M., Khong H., Dai Z., Huang X.F., Wargo J.A., Cooper Z.A., et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J. Immunol 2014, 193:4722-4731.
29. Marcenaro E., Carlomagno S., Pesce S., Moretta A., Sivori S. NK/DC crosstalk in anti-viral response. Adv. Exp. Med. Biol 2012, 946:295-308.
30. Yamamoto M., Tatsumi T., Miyagi T., Tsunematsu H., Aketa H., Hosui A., et al. alpha-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells. Clin. Exp. Immunol 2011, 165:211-219.
31. Nguyen-Pham T.N., Yang D.H., Nguyen T.A.T., Lim M.S., Hong C.Y., Kim M.H., et al. Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy. Cell. Mol. Immunol 2012, 9:45-53.
32. Nguyen-Pham T.N., Im C.M., Nguyen T.A.T., Lim M.S., Hong C.Y., Kim M.H., et al. Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma. Leukemia Res 2011, 35:1241-1247.
33. Tanaka S., Koizumi S., Masuko K., Makiuchi N., Aoyagi Y., Quivy E., et al. Toll-like receptor-dependent IL-12 production by dendritic cells is required for activation of natural killer cell-mediated type-1 immunity induced by Chrysanthemum coronarium L. Int. Immunopharmacol 2011, 11:226-232.
34. Boudreau J.E., Stephenson K.B., Wang F.A., Ashkar A.A., Mossman K.L., Lenz L.L., et al. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res 2011, 71:2497-2506.
35. Andrews D.M., Scalzo A.A., Yokoyama W.M., Smyth M.J., Degli-Esposti M.A. Functional interactions between dendritic cells and NK cells during viral infection. Nat. Immunol 2003, 4:175-181.
36. Van Elssen C.H.M.J., Vanderlocht J., Frings P.W.H., Senden-Gijsbers B.L.M.G., Schnijderberg M.C.A., van Gelder M., et al. Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells. Eur. J. Immunol 2010, 40:3138-3149.
37. Shimizu K., Asakura M., Fujii S. Prolonged antitumor NK cell reactivity elicited by CXCL10-Expressing dendritic cells licensed by CD40L(+) CD4(+) memory T cells. J. Immunol 2011, 186:5927-5937.
38. Nakayama M., Takeda K., Kawano M., Takai T., Ishii N., Ogasawara K. Natural killer (NK)-dendritic cell interactions generate MHC class II-dressed NK cells that regulate CD4(+) T cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18360-18365.
39. Vitale M., Della Chiesa M., Carlomagno S., Pende D., Arico M., Moretta L., et al. NK-dependent DC maturation is mediated by TNF alpha and IFN gamma released upon engagement of the NKp30 triggering receptor. Blood 2005, 106:566-571.
40. Wai L.E., Garcia J.A., Martinez O.M., Krams S.M. Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells. J. Immunol 2011, 186:222-229.
41. da Silva R.B., Graf C., Munz C. Cytoskeletal stabilization of inhibitory interactions in immunologic synapses of mature human dendritic cells with natural killer cells. Blood 2011, 118:6487-6498.